The Centre for Molecular Medicine Norway (NCMM, www.ncmm.uio.no) was established in 2007 as a national partnership institution with the European Molecular Biology Laboratory (www.embl.org) together with similar centres in Sweden and Finland under the Nordic EMBL Partnership. NCMM is inaugurated as joint venture between the University of Oslo as host, the Research Council of Norway and Health Region South East.
The overall objective of NCMM is to facilitate translation of discoveries in basic medical research into clinical practice. NCMM will focus particularly on disease mechanisms where Norway has clear strengths and will investigate mechanisms of non-communicable diseases such as cancer, cardiovascular and CNS-related disease and immune disorders. The Nordic EMBL partnership aims to exploit emerging technologies as part of a process towards molecular and personalized medicine and will capitalize on synergies within the Nordic region. NCMM will develop and adapt technologies for personalized medical applications and will be expected to unravel new diagnostic methods and drug targets. Furthermore, NCMM will develop new therapeutic strategies for commercial exploitation and have a strategy that includes handling of Intellectual Property Rights before interfacing with biotechnology and bio-pharmaceutical industries. NCMM is also a partner in the EU-ESFRI project European Advanced Translational Infrastructure (www.EATRIS.eu) planning the future of translational research in Europe. NCMM is located in the University of Oslo and National Hospital Biomedical Campus in the Oslo Research Park and Preclinical Medicine buildings, has three identified founding partners (O.P. Ottersen, K. Taskén, S. Krauss) and will hire five to six new group leaders during the next 3 - 4 years.
NCMM is now seeking outstanding international candidates for the prestigious positions of:

Get in touch with the University of Oslo